Schroder Investment Management Group Sells 622,359 Shares of Insmed Incorporated (NASDAQ:INSM)

Schroder Investment Management Group lowered its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 69.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 268,063 shares of the biopharmaceutical company's stock after selling 622,359 shares during the period. Schroder Investment Management Group owned approximately 0.15% of Insmed worth $18,461,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC raised its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed during the 4th quarter valued at $47,000. Smartleaf Asset Management LLC lifted its holdings in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Insmed in the fourth quarter worth $86,000.

Insiders Place Their Bets

In other news, CFO Sara Bonstein sold 1,066 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $7,573,950.36. This trade represents a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 2,978 shares of the company's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the completion of the sale, the chief executive officer now directly owns 392,589 shares in the company, valued at approximately $24,874,439.04. The trade was a 0.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 532,207 shares of company stock worth $41,683,028 over the last three months. Company insiders own 4.60% of the company's stock.

Analyst Ratings Changes

INSM has been the topic of a number of research reports. Guggenheim restated a "buy" rating and set a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. JPMorgan Chase & Co. upped their target price on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Wells Fargo & Company lifted their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Trading Down 1.6 %

INSM traded down $1.09 during midday trading on Monday, reaching $68.09. 3,666,731 shares of the company's stock traded hands, compared to its average volume of 2,242,350. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a fifty day moving average of $77.59 and a two-hundred day moving average of $73.93. The stock has a market capitalization of $12.32 billion, a price-to-earnings ratio of -12.18 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, equities analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.